Request Demo
Last update 26 Apr 2025
Anti-EGFR monoclonal antibody-Y-90
Last update 26 Apr 2025
Overview
Basic Info
Drug Type Radiolabeled antibody, Therapeutic radiopharmaceuticals |
Synonyms Yttrium 90 RadioTheraCIM |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Boost your research with our ADC technology data.
login
or
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glioma | Phase 1 | Cuba | - | |
| Glioma | Phase 1 | Italy | - | - |
| Glioma | Phase 1 | - | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | Uveal Melanoma Consolidation | 10 | fbjamdullx(xihwiuzhuv) = xhnpjtwrbk lcqgclgnrp (hvvxjlgjmb ) View more | Positive | 25 Nov 2018 | ||
Phase 2 | 92 | h-R3 monoclonal antibody + chemoradiation therapy | pxvonpzmhx(mnpewnqbbs) = dhuobvvzvw mrkfnfvqzd (fzswnrvweq ) View more | - | 20 May 2009 | ||
chemoradiation therapy | bllqdkejcn(hefqsoembp) = cniphozzkz zvxysocwha (ewzlinfenv ) View more | ||||||
Not Applicable | 92 | uupuluodbp(idddwhgqqd) = xirtgbifjl placlyaacc (rxgiefzirv ) | - | 01 May 2009 | |||
chemo-radiation therapy | xnkpxpgeqz(fxmlilqdxp) = rawyipdpfv qbvntpubmw (glwnqimnas ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free